3/11
02:33 pm
ctxr
Citius Pharmaceuticals (CTXR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $6.00 price target on the stock.
Medium
Report
Citius Pharmaceuticals (CTXR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $6.00 price target on the stock.
3/6
03:17 pm
ctxr
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]
Low
Report
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]
2/24
08:00 am
ctxr
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Medium
Report
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
2/13
08:27 am
ctxr
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ [Yahoo! Finance]
High
Report
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ [Yahoo! Finance]
2/13
08:00 am
ctxr
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
High
Report
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
12/23
05:16 pm
ctxr
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
12/23
04:30 pm
ctxr
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
High
Report
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update